• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2016年哥伦比亚的癌症风险管理

Cancer risk management in Colombia, 2016.

作者信息

Ramírez-Barbosa Paula, Acuña Merchán Lizbeth

机构信息

Cuenta de Alto Costo- Fondo Colombiano de Enfermedades de Alto Costo. Ministerio de Salud y Proteccion Social, Bogota, Colombia.

出版信息

Colomb Med (Cali). 2018 Mar 30;49(1):128-134. doi: 10.25100/cm.v49i1.3882.

DOI:10.25100/cm.v49i1.3882
PMID:29983473
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6018822/
Abstract

OBJECTIVE

To describe the outcomes of risk management indicators for five types of cancer in population that is affiliated to the General System of Social Security in Health, in six cities of Colombia.

METHODS

Based on the data from the administrative cancer registry for the period 2016, the High Cost Disease Fund (CAC in Spanish) as a technical organization of the Colombian health system, processed and analyzed the data for the calculation of risk management indicators established in consensus based on the evidence found in six cities.

RESULTS

There is a diversity in the indicators results found among the different cities, evidencing strengths and weaknesses in each of them for the different types of cancer. From the set of indicators, those with the best results presented are related to the greater detection of cancer in early stages or in situ, as well as a decrease in mortality, especially in colorectal and in gastric cancer. Most indicators in gastric cancer showed optimal results. Important measurements such as the opportunity for diagnosis and treatment are below the proposed standard for most types in all the six cities.

CONCLUSIONS

The descriptive analysis of cancer risk management indicators shows certain weaknesses in the quality and timeliness of the care of cancer patients, the standards agreed upon in the consensus with the different actors of the system are not being reached, situation which may be due to a reality of problems of the Colombian health system, as well as deficiencies in the quality of the report to the CAC.

摘要

目的

描述哥伦比亚六个城市中隶属于健康社会保障总体系人群的五种癌症风险管理指标的结果。

方法

基于2016年行政癌症登记处的数据,作为哥伦比亚卫生系统技术组织的高成本疾病基金(西班牙语为CAC)处理并分析了这些数据,以计算基于六个城市中所发现证据经共识确定的风险管理指标。

结果

不同城市间指标结果存在差异,表明每种癌症在各个城市都有优势和劣势。从指标集来看,呈现出最佳结果的指标与癌症早期或原位癌的更多检出以及死亡率下降有关,尤其是在结直肠癌和胃癌方面。胃癌的大多数指标显示出最佳结果。在所有六个城市中,大多数类型的癌症在诊断和治疗时机等重要指标低于提议标准。

结论

癌症风险管理指标的描述性分析显示,癌症患者护理的质量和及时性存在一定弱点,未达到与系统中不同行为者达成共识的标准,这种情况可能归因于哥伦比亚卫生系统的实际问题以及向高成本疾病基金报告质量的不足。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c786/6018822/6a2d75e294b3/1657-9534-cm-49-01-00128-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c786/6018822/212928ba858b/1657-9534-cm-49-01-00128-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c786/6018822/6a2d75e294b3/1657-9534-cm-49-01-00128-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c786/6018822/212928ba858b/1657-9534-cm-49-01-00128-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c786/6018822/6a2d75e294b3/1657-9534-cm-49-01-00128-gf2.jpg

相似文献

1
Cancer risk management in Colombia, 2016.2016年哥伦比亚的癌症风险管理
Colomb Med (Cali). 2018 Mar 30;49(1):128-134. doi: 10.25100/cm.v49i1.3882.
2
Quality of death certification in Colombia.哥伦比亚的死亡证明质量。
Colomb Med (Cali). 2018 Mar 30;49(1):121-127. doi: 10.25100/cm.v49i1.3155.
3
Evaluation of institutional cancer registries in Colombia.哥伦比亚机构癌症登记处的评估。
Rev Panam Salud Publica. 1999 Sep;6(3):202-6. doi: 10.1590/s1020-49891999000800008.
4
Use of the six core surgical indicators from the Lancet Commission on Global Surgery in Colombia: a situational analysis.利用柳叶刀全球外科学委员会的六个核心外科指标在哥伦比亚进行情况分析。
Lancet Glob Health. 2020 May;8(5):e699-e710. doi: 10.1016/S2214-109X(20)30090-5.
5
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
6
Italian cancer figures, report 2012: Cancer in children and adolescents.《2012年意大利癌症数据报告:儿童和青少年癌症》
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225.
7
Estimating the cost of operating cancer registries: Experience in Colombia.估算癌症登记处的运营成本:哥伦比亚的经验。
Cancer Epidemiol. 2016 Dec;45 Suppl 1(Suppl 1):S13-S19. doi: 10.1016/j.canep.2016.09.014. Epub 2016 Oct 17.
8
Incidence and Prevalence of Cancer in Colombia: The Methodology Used Matters.哥伦比亚癌症的发病率和患病率:所采用的方法很重要。
J Glob Oncol. 2018 Sep;4:1-7. doi: 10.1200/JGO.17.00008. Epub 2017 Jul 6.
9
Comprehensive assessment of population-based cancer registries: an experience in Colombia.基于人群的癌症登记处综合评估:哥伦比亚的经验
J Registry Manag. 2014 Fall;41(3):128-34.
10
Rheumatoid arthritis in Colombia: a clinical profile and prevalence from a national registry.哥伦比亚的类风湿关节炎:一项全国性登记研究的临床特征和流行率。
Clin Rheumatol. 2021 Sep;40(9):3565-3573. doi: 10.1007/s10067-021-05710-x. Epub 2021 Mar 27.

引用本文的文献

1
Survival of patients living with HIV and cancer in Cali, Colombia.HIV 合并癌症患者在哥伦比亚卡利市的生存状况。
Colomb Med (Cali). 2023 Sep 30;54(3):e2015558. doi: 10.25100/cm.v54i3.5588. eCollection 2023 Jul-Sep.
2
Survival in stomach cancer: analysis of a national cancer information system and a population-based cancer registry in Colombia.胃癌患者的生存状况:哥伦比亚国家癌症信息系统和基于人群的癌症登记处的分析。
Colomb Med (Cali). 2022 Dec 30;53(4):e2025126. doi: 10.25100/cm.v53i4.5126. eCollection 2022 Oct-Dec.
3
Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS.

本文引用的文献

1
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.全球癌症生存趋势监测 2000-14 年(CONCORD-3):对来自 71 个国家 322 个基于人群的登记处的 37513025 名诊断患有 18 种癌症之一的患者的个体记录进行分析。
Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31.
2
The nutritional risk in oncology: a study of 1,453 cancer outpatients.肿瘤患者的营养风险:一项 1453 例癌症门诊患者的研究。
Support Care Cancer. 2012 Aug;20(8):1919-28. doi: 10.1007/s00520-012-1387-x.
3
用MSAS测量西班牙和哥伦比亚肿瘤患者的症状患病率。
Cancers (Basel). 2022 Mar 23;14(7):1624. doi: 10.3390/cancers14071624.
4
National Cancer Information System Within the Framework of Health Insurance in Colombia: A Real-World Data Approach to Evaluate Access to Cancer Care.哥伦比亚医疗保险框架内的国家癌症信息系统:一种评估癌症护理可及性的真实世界数据方法。
JCO Glob Oncol. 2021 Aug;7:1329-1340. doi: 10.1200/GO.21.00155.
5
Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.哥伦比亚开展药物流行病学研究的二级医疗保健数据的可用性:系统评价。
Pharmacol Res Perspect. 2020 Oct;8(5):e00661. doi: 10.1002/prp2.661.
6
Space-time clustering of childhood leukemia in Colombia: a nationwide study.哥伦比亚儿童白血病的时空聚集性:一项全国性研究。
BMC Cancer. 2020 Jan 20;20(1):48. doi: 10.1186/s12885-020-6531-2.
7
Preliminary analysis of single-nucleotide polymorphisms in IL-10, IL-4, and IL-4Rα genes and profile of circulating cytokines in patients with gastric Cancer.胃癌患者白细胞介素-10、白细胞介素-4和白细胞介素-4受体α基因单核苷酸多态性的初步分析及循环细胞因子谱
BMC Gastroenterol. 2018 Dec 10;18(1):184. doi: 10.1186/s12876-018-0913-9.
8
The Cancer Observatory of Cali, a priority.卡利癌症观测站,一项优先事项。
Colomb Med (Cali). 2018 Sep 30;49(3):249-250.
GRADE guidelines: 3. Rating the quality of evidence.
GRADE 指南:3. 评估证据质量。
J Clin Epidemiol. 2011 Apr;64(4):401-6. doi: 10.1016/j.jclinepi.2010.07.015. Epub 2011 Jan 5.
4
AGREE II: advancing guideline development, reporting and evaluation in health care.AGREE II:推进医疗保健领域的指南制定、报告与评估
J Clin Epidemiol. 2010 Dec;63(12):1308-11. doi: 10.1016/j.jclinepi.2010.07.001. Epub 2010 Jul 24.
5
The PICO strategy for the research question construction and evidence search.用于构建研究问题和检索证据的PICO策略。
Rev Lat Am Enfermagem. 2007 May-Jun;15(3):508-11. doi: 10.1590/s0104-11692007000300023.
6
Utilization of the PICO framework to improve searching PubMed for clinical questions.利用PICO框架改进在PubMed中搜索临床问题的方法。
BMC Med Inform Decis Mak. 2007 Jun 15;7:16. doi: 10.1186/1472-6947-7-16.